AAAAAA

   
Results: 1-25 | 26-26
Results: 1-25/26

Authors: Scharrer, I Ehrlich, HJ
Citation: I. Scharrer et Hj. Ehrlich, Lack of evidence for increased inhibitor incidence in patients switched from plasma-derived to recombinant factor VIII, HAEMOPHILIA, 7(4), 2001, pp. 346-348

Authors: Scandella, DH Nakai, H Felch, M Mondorf, W Scharrer, I Hoyer, LW Saenko, EL
Citation: Dh. Scandella et al., In hemophilia A and autoantibody inhibitor patients: The factor VIII A2 domain and light chain are most immunogenic, THROMB RES, 101(5), 2001, pp. 377-385

Authors: Kacer, B Hattenbach, LO Horle, S Scharrer, I Kroll, P Koch, F
Citation: B. Kacer et al., Central retinal vein occlusion and nonarteritic ischemic optic neuropathy in 2 patients with mild iron deficiency anemia, OPHTHALMOLA, 215(2), 2001, pp. 128-131

Authors: Scharrer, I Brackmann, HH Sultan, Y Abshire, T Gazengel, C Ragni, M Gorina, E Vosburgh, E Kellermann, E
Citation: I. Scharrer et al., Efficacy of a sucrose-formulated recombinant factor VIII used for 22 surgical procedures in patients with severe haemophilia A, HAEMOPHILIA, 6(6), 2000, pp. 614-618

Authors: Beeck, H Nagel, D Pindur, G Scharrer, I Preiss, A Seiler, D Hellstern, P
Citation: H. Beeck et al., Measurement of antithrombin activity by thrombin-based and by factor Xa-based chromogenic substrate assays, BL COAG FIB, 11(2), 2000, pp. 127-135

Authors: Rothschild, C Gill, J Scharrer, I Bray, G
Citation: C. Rothschild et al., Transient inhibitors in the recombinate PUP study, THROMB HAEM, 84(1), 2000, pp. 145-146

Authors: Abshire, TC Brackmann, HH Scharrer, I Hoots, K Gazengel, C Powell, JS Gorina, E Kellermann, E Vosburgh, E
Citation: Tc. Abshire et al., Sucrose formulated recombinant human antihemophilic factor VIII is safe and efficacious for treatment of hemophilia A in home therapy - Results of a multicenter, international, clinical investigation, THROMB HAEM, 83(6), 2000, pp. 811-816

Authors: Hogan, KA Lord, ST Okumura, N Terasawa, F Galankis, DK Scharrer, I Gorkun, OV
Citation: Ka. Hogan et al., A functional assay suggests that heterodimers exist in two C-terminal gamma-chain dysfibrinogens: Matsumoto I and Vlissingen/Frankfurt IV, THROMB HAEM, 83(4), 2000, pp. 592-597

Authors: von Depka, M Nowak-Gottl, U Eisert, R Dieterich, C Barthels, M Scharrer, I Ganser, A Ehrenforth, S
Citation: M. Von Depka et al., Increased lipoprotein (a) levels as an independent risk factor for venous thromboembolism, BLOOD, 96(10), 2000, pp. 3364-3368

Authors: Scharrer, I Grossmann, R
Citation: I. Scharrer et R. Grossmann, Acquired inhibitory body hemophilia, ANAESTHESIS, 49(1), 2000, pp. 34-42

Authors: Ehrenforth, S Klinke, S Prondzinski, MVD Kreuz, W Ganser, A Scharrer, I
Citation: S. Ehrenforth et al., Resistance to activated protein C in patients with deep vein thrombosis and or pulmonary embolism: molecular genetic study of prevalence among patients from various regions in Germany, DEUT MED WO, 124(25-26), 1999, pp. 783-787

Authors: Scharrer, I
Citation: I. Scharrer, Recombinant factor VIIa for patients with inhibitors to factor VIII or IX or factor VII deficiency, HAEMOPHILIA, 5(4), 1999, pp. 253-259

Authors: Scharrer, I Bray, GL Neutzling, O
Citation: I. Scharrer et al., Incidence of inhibitors in haemophilia A patients - a review of recent studies of recombinant and plasma-derived factor VIII concentrates, HAEMOPHILIA, 5(3), 1999, pp. 145-154

Authors: Brackmann, HH Lenk, H Scharrer, I Auerswald, G Kreuz, W
Citation: Hh. Brackmann et al., German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies, HAEMOPHILIA, 5(3), 1999, pp. 203-206

Authors: Ehrenforth, S Prondsinski, MV Aygoren-Pursun, E Scharrer, I Ganser, A
Citation: S. Ehrenforth et al., Study of the prothrombin gene 20201 GA variant in FV : Q(506) carriers in relationship to the presence or absence of juvenile venous thromboembolism, ART THROM V, 19(2), 1999, pp. 276-280

Authors: Schmidt, R Scheuermann, EH Viertel, A Geiger, H Scharrer, I
Citation: R. Schmidt et al., Antiphospholipid antibody syndrome, MED KLIN, 94(2), 1999, pp. 93-100

Authors: Ehrenforth, S Junker, R Koch, HG Kreuz, W Munchow, N Scharrer, I Nowak-Gottl, U
Citation: S. Ehrenforth et al., Multicentre evaluation of combined prothrombotic: defects associated with thrombophilia in childhood, EUR J PED, 158, 1999, pp. S97-S104

Authors: Heller, C Becker, S Scharrer, I Kreuz, W
Citation: C. Heller et al., Prothrombotic risk factors in childhood stroke and venous thrombosis, EUR J PED, 158, 1999, pp. S117-S121

Authors: Becker, S Schneider, W Kreuz, W Jacobi, G Scharrer, I Nowak-Gottl, U
Citation: S. Becker et al., Post-trauma coagulation and fibrinolysis in children suffering from severecerebro-cranial trauma, EUR J PED, 158, 1999, pp. S197-S202

Authors: Ehrenforth, S Schenk, JF Scharrer, I
Citation: S. Ehrenforth et al., Liver damage induced by coumarin anticoagulants, SEM THROMB, 25(1), 1999, pp. 79-83

Authors: Scharrer, I
Citation: I. Scharrer, Diagnosis and therapy of coagulation disorders in operative orthopedics, ORTHOPADE, 28(4), 1999, pp. 316

Authors: Kurth, AA Ludwig, G Scharrer, I
Citation: Aa. Kurth et al., Prevalence, pathophysiology, diagnosis, and treatment of Willebrand syndrome in orthopedic-trauma patients, ORTHOPADE, 28(4), 1999, pp. 366-374

Authors: Hattenbach, LO Wellermann, G Steinkamp, GWK Scharrer, I Koch, FHJ Ohrloff, C
Citation: Lo. Hattenbach et al., Visual outcome after treatment with low-dose recombinant tissue plasminogen activator or hemodilution in ischemic central retinal vein occlusion, OPHTHALMOLA, 213(6), 1999, pp. 360-366

Authors: Schachinger, V Britten, MB Elsner, M Walter, DH Scharrer, I Zeiher, AM
Citation: V. Schachinger et al., A positive family history of premature coronary artery disease is associated with impaired endothelium-dependent coronary blood flow regulation, CIRCULATION, 100(14), 1999, pp. 1502-1508

Authors: Hattenbach, LO Klais, C Scharrer, I
Citation: Lo. Hattenbach et al., Heparin cofactor II deficiency in central retinal vein occlusion, ACT OPHTH S, 76(6), 1998, pp. 758-759
Risultati: 1-25 | 26-26